Takeda Oncology’s Exkivity treats non-small lung cancer in patients with EGFR exon 20 insertion mutations. This is the second approval for this mutation and the first oral therapy.
Formulary Watch
Latest News
All News
Advertisement
The FDA has set a Prescription Drug User Fee Act target action date of April 30, 2022.
The agency has granted accelerated approval to Brukinsa as a second-line treatment for patients with marginal zone lymphoma, a group of slow-growing non-Hodgkin lymphomas.
The plan will cover administration of the booster for those with cancer or who are immunocompromised.
Alinia and Sutent have been removed from the drug lists because of the introduction of generic therapies.
Real-world data show Erleada prolonged survival in both metastatic and non-metastatic castration-sensitive prostate cancer.
The affected lots of this rare disease therapy have been contaminated with yeast, mold, and bacteria, which could lead to life-threatening infections.
The PDUFA date has been set for July 12, 2022.
Jardiance demonstrated a 21% relative risk reduction for the composite primary endpoint of cardiovascular death or hospitalization for heart failure.
Advertisement
Officials with OptumRx predict four new therapies that are expected to an impact on patients and on the market.
Point32Health is the name of the not-for-profit health care organization formed by the merger of Harvard Pilgrim Health Care and Tufts Health Plan.
Investigators found patients with COPD taking Anoro Ellipta had low overall on-treatment exacerbation rates, which can reduce medical costs due to increased adherence to therapy.
The lot contains kits with the incorrect solution for diluting vancomycin, which could lead to doses above or below recommended levels.
Investigators find there is strong adherence soon after patients fill prescriptions but less consistent use after initial treatment.
ICER’s updated analysis uses observational, real-world data for three therapies — Takhzyro, Haegarda, and Cinryze.
The therapy, to be launched in October, is delivered quickly to the bloodstream by targeting the upper nasal space.
The CDC and the FDA have updated their recommendations for the 2021-2022 flu season.
American Academy of Sleep Medicine’s guideline recommends Wakix to treat excessive daytime sleepiness and cataplexy in adults with narcolepsy.
The FDA’s review of the JAK inhibitor class concluded there is an increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death with these arthritis and ulcerative colitis medicines.
The product is considered “super potent” with a higher dose that could result in serious cardiac toxicities.
Pharmacists are referring patients elsewhere or are shifting patients who were using the IV form to the subcutaneous injection. The NIH has also recommended using Kevzara as an alternative where there are shortages of Actemra.
Investigators says Janssen’s Invega Hafyera offers longer-term symptom control with the fewest doses per year, which may support greater patient adherence.
The approval follows the FDA’s Oncologic Drugs Advisory Committee voting 5-3 in favor of maintaining the approval despite a confirmatory trial that found Keytruda did not meet the end points of overall survival and progression-free survival.
Florida’s First Choice Neurology has provided Aduhelm to patients through the Biogen access program.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Optimal Physical Activity for Preventing Digestive System Cancers
2
Tubeless AID Systems Boost HRQoL in Type 1 Diabetes
3
Navigating Female Sexuality in Midlife Requires Provider Nuance and Patient Advocacy
4
Modeling Finds the Timing of Modafinil to Treat Narcolepsy Matters for Efficacy
5
